The Uromigos
The Uromigos
Advertisement
The UromigosThe Uromigos | November 20, 2023
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
Listen Now
The UromigosThe Uromigos | November 14, 2023
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.
The UromigosThe Uromigos | November 7, 2023
Brian is joined by Drs. Agarwal, Dorff, McKay, and Morris to review the state of radioligand therapy.
The UromigosThe Uromigos | November 6, 2023
Tom is joined by Drs. Chang, Daneshmand, and Grivas to discuss new therapies in NMIBC and BCG-refractory NMIBC.
The UromigosThe Uromigos | October 31, 2023
Silke Gillessen, MD, PhD recaps some of the kidney, bladder, and prostate cancer data from this year's ESMO meeting.
The UromigosThe Uromigos | October 31, 2023
Brian and Tom give details on the various panels that will take place at The Uromigos Live & Unplugged 2023.
The UromigosThe Uromigos | October 31, 2023
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
The UromigosThe Uromigos | November 13, 2023
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
The UromigosThe Uromigos | October 30, 2023
Michiel Van der Heijdan, MD, PhD, discusses EV-302 and CheckMate-901 on EV plus pembrolizumab and nivolumab plus ipilimumab.
The UromigosThe Uromigos | October 30, 2023
Yohann Loriot, MD, PhD, gives an update on the use of erdafitinib within the THOR randomized phase 3 trial.
The UromigosThe Uromigos | October 30, 2023
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
The UromigosThe Uromigos | October 30, 2023
Dr. Brad McGregor discusses the DAD trial on sacituzumab govitecan plus enfortumab vedotin for the treatment of mUC.
The UromigosThe Uromigos | October 30, 2023
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
The UromigosThe Uromigos | October 13, 2023
Silke Gillessen, MD, PhD joins us to discuss the upcoming ESMO conference and panels of interest to look out for.
The UromigosThe Uromigos | October 11, 2023
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
The UromigosThe Uromigos | October 5, 2023
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
The UromigosThe Uromigos | September 28, 2023
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
The UromigosThe Uromigos | October 16, 2023
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
The UromigosThe Uromigos | September 14, 2023
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Matthew D. Galsky, MDThe Uromigos | September 7, 2023
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Advertisement
Advertisement
Advertisement